

Marbofloxacin

Catalog No: tcsc1892



Available Sizes

Size: 100mg

Size: 500mg



Specifications

CAS No:

115550-35-1

Formula:

$C_{17}H_{19}FN_4O_4$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 3.8 mg/mL (10.49 mM)

Observed Molecular Weight:

362.36

Product Description

Marbofloxacin is a potent antibiotic of which depends upon its inhibition of DNA-gyrase. Marbofloxacin is a synthetic, broad spectrum bactericidal agent.


Target: DNA-gyrase

Marbofloxacin is a third-generation fluoroquinolone for veterinary use, the antimicrobial of which depends upon its inhibition of DNA-

gyrase and topoisomerase IV. With a broad spectrum bactericidal activity and good efficacy, marbofloxacin is indicated for dermatological, respiratory and urinary tract infections due to both Gram-positive and Gram-negative bacteria and Mycoplasma [1].

Administration of Marbofloxacin at 6 mg/kg once daily for 7 days in a Staphylococcus aureus infection in tissue cages in ponies is not effective for the elimination of S. aureus infections from secluded sites [2]. The pharmacokinetic properties of marbofloxacin were investigated in 6 horses after i.v., subcutaneous and oral administration of a single dose of 2 mg/kg bwt and the minimal inhibitory concentrations (MIC) assessed for bacteria isolated from equine infectious pathologies. The clearance of marbofloxacin was mean \pm s.d. 0.25 \pm 0.05 l/kg/h and the terminal half-life 756 \pm 1.99 h. The marbofloxacin absolute bioavailabilities after subcutaneous and oral administration were 98 \pm 11% and 62 \pm 8%, respectively. Considering the breakpoint values of efficacy indices for fluoroquinolones, a marbofloxacin dosage regimen of 2 mg/kg bwt/24 h by i.v., subcutaneous or oral routes was more appropriate for enterobacteriaceae than for S. aureus [3].

Toxicity: cramps; vomiting; anorexia; soft stools; diarrhoea



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!